BMY Sep 2024 30.000 call
| Previous close | 11.27 |
| Open | 11.27 |
| Bid | 9.75 |
| Ask | 11.75 |
| Strike | 30.00 |
| Expiry date | 2024-09-20 |
| Day's range | 11.27 - 11.27 |
| Contract range | N/A |
| Volume | |
| Open interest | 23 |
BenzingaFDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
On Thursday, the FDA approved Geron Corporation's (NASDAQ:GERN) Rytelo (imetelstat) for adult patients with low-to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia. The approval covers patients requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents. In March, by a 12-to-2 margin, the FDA adcomm panel voted in favor of the benefits of imetelstat, st
Insider MonkeyHere’s Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY)
We recently published the list of 11 stocks Jim Cramer is bearish on. Bristol-Myers Squibb Co (NYSE:BMY) ranks 2nd in the list. Click to see the full list of 11 stocks Cramer is bearish on. In this article we will take a deeper look at BMY and find out whether Cramer’s thesis holds any weight. […]
ZacksBristol Myers (BMY) Reports Positive Data on Breyanzi, Opdivo (Revised)
Bristol Myers (BMY) announces positive data from three studies evaluating CAR T cell therapy Breyanzi (liso-cel) and three updated analyses on studies evaluating Opdivo at ASCO.
